Chang S H, Kim S H, Lee W K, Kim H J, Choi S H, Park J H, Jang H S, Chung G H, Kwon T H, Kim D H, Yang M S, Jang Y S
Faculty of Biological Sciences and The Institute for Molecular Biology and Genetics, Chonbuk National University, Chonju, Korea.
Mol Cells. 1998 Oct 31;8(5):585-93.
Membrane glycoprotein 350 (gp350) of the Epstein-Barr virus (EBV) is considered as a major target for vaccine development, since the gp350 has been identified as the virus' mediator for receptor interaction and as an inducer of specific in vitro virus-neutralizing antibodies. In an initial attempt to develop an effective DNA vaccine against an EBV infection, gp350 genes were isolated from SNU-20 and SNU-1103 which are the EBV-infected lymphoblastoid cell lines established in Korea. In addition, the nucleotide sequences of the gp350 genes were determined and compared with those of other EBV strains such as B95-8, P3HR-1/AG876 and M81. Sequence analysis showed that similar high degrees of homology between 2 EBV strains derived from African Burkitt's lymphoma, P3HR-1 and AG876, was shown between the gp350 genes isolated from 2 EBV-infected lymphoblastoid cell lines established in Korea. Furthermore, these 2 Korean and 2 African strains displayed nearly identical patterns of sequence variations from B95-8. In addition, the sequence of the isolated gp350 genes, which have been reported to be associated with the biology of EBV infection, is analyzed.
爱泼斯坦-巴尔病毒（EBV）的膜糖蛋白350（gp350）被认为是疫苗开发的主要靶点，因为gp350已被确定为该病毒与受体相互作用的介质以及特异性体外病毒中和抗体的诱导剂。在首次尝试开发针对EBV感染的有效DNA疫苗时，从韩国建立的EBV感染的淋巴母细胞系SNU - 20和SNU - 1103中分离出gp350基因。此外，测定了gp350基因的核苷酸序列，并与其他EBV毒株如B95 - 8、P3HR - 1/AG876和M81的序列进行了比较。序列分析表明，源自非洲伯基特淋巴瘤的2株EBV毒株P3HR - 1和AG876之间的gp350基因具有高度同源性，与从韩国建立的2株EBV感染的淋巴母细胞系中分离出的gp350基因相似。此外，这2株韩国毒株和2株非洲毒株与B95 - 8的序列变异模式几乎相同。另外，对已报道与EBV感染生物学相关的分离出的gp350基因序列进行了分析。
